 Inhibrx Inc NASDAQ: INBX has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered multi-specific therapeutic candidate based on a single-domain antibody platform. 